One-carbon metabolism and breast cancer: an epidemiological perspective

被引:66
作者
Xu, Xinran [1 ]
Chen, Jia [1 ,2 ,3 ]
机构
[1] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
one-carbon; breast cancer; folate; genetic polymorphism; DNA methylation; epidemiology; METHIONINE SYNTHASE REDUCTASE; MODERATE FOLATE-DEPLETION; DNA METHYLATION; METHYLENETETRAHYDROFOLATE-REDUCTASE; PLASMA HOMOCYSTEINE; D919G POLYMORPHISM; DIETARY-FOLATE; DELETION POLYMORPHISM; POSTMENOPAUSAL WOMEN; MATHEMATICAL-MODEL;
D O I
10.1016/S1673-8527(08)60108-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One-carbon metabolism is a network of biological reactions that plays critical role in DNA methylation and DNA synthesis, and in turn, facilitates the cross-talk between genetic and epigenetic processes. Genetic polymorphisms and supplies of cofactors (e.g. folate, vitamins B) involved in this pathway have been shown to influence cancer risk and even survival. In this review, we summarized the epidemiological evidence for one-carbon metabolism, from both genetics and lifestyle aspects, in relation to breast cancer risk. We also discussed this pathway in relation to breast cancer survival and the modulation of one-carbon polymorphism in chemotherapy. Emerging evidence on modulation of DNA methylation by one-carbon metabolism suggests that disruption of epigenome might have been the underlying mechanism. More results are expected and will be translated to guidance to the general population for disease prevention as well as to clinicians for treatment and management of the disease.
引用
收藏
页码:203 / 214
页数:12
相关论文
共 91 条
[71]   Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer [J].
Stevenson, JP ;
Redlinger, M ;
Kluijtmans, LAJ ;
Sun, WJ ;
Algazy, K ;
Giantonio, B ;
Haller, DG ;
Hardy, C ;
Whitehead, AS ;
O'Dwyer, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) :4081-4087
[72]   Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [J].
Stolzenberg-Solomon, RZ ;
Chang, SC ;
Leitzmann, MF ;
Johnson, KA ;
Johnson, C ;
Buys, SS ;
Hoover, RN ;
Ziegler, RG .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (04) :895-904
[73]   MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) [J].
Toffoli, G ;
Veronesi, A ;
Boiocchi, M ;
Crivellari, D .
ANNALS OF ONCOLOGY, 2000, 11 (03) :373-374
[74]   MTHFR variants reduce the risk of G:C→A:T transition mutations within the p53 tumor suppressor gene in colon tumors [J].
Ulrich, C. M. ;
Curtin, K. ;
Samowitz, W. ;
Bigler, J. ;
Potter, J. D. ;
Caan, B. ;
Slattery, M. L. .
JOURNAL OF NUTRITION, 2005, 135 (10) :2462-2467
[75]  
Ulrich CM, 2000, CANCER EPIDEM BIOMAR, V9, P1381
[76]   Folate and cancer prevention: a closer look at a complex picture [J].
Ulrich, Cornelia M. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 86 (02) :271-273
[77]   Mathematical modeling: Epidemiology meets systems biology [J].
Ulrich, Cornelia M. ;
Nijhout, H. Frederik ;
Reed, Michael C. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (05) :827-829
[78]   Functional inference of the methylenetetrahydrofolate reductase 677 C > T and 1298A > C polymorphisms from a large-scale epidemiological study [J].
Ulvik, Arve ;
Ueland, Per M. ;
Fredriksen, Ase ;
Meyer, Klaus ;
Vollset, Stein Emil ;
Hoff, Geir ;
Schneede, Jorn .
HUMAN GENETICS, 2007, 121 (01) :57-64
[79]  
van Engeland M, 2003, CANCER RES, V63, P3133
[80]   Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review [J].
Velicer, Christine M. ;
Ulrich, Cornelia M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :665-673